Spravato (esketamine) nasal spray is an FDA-approved treatment for treatment-resistant depression (TRD) and major depressive disorder (MDD) with acute suicidal ideation or behavior (MDSI) in adults who have not responded to at least two oral antidepressants. Clear Path administers every Spravato session in-person under direct psychiatric supervision at our Pembroke Pines, Florida and Orange County, California locations, in full compliance with the FDA Risk Evaluation and Mitigation Strategy (REMS) program.
Starting Spravato Treatment at Clear Path in Pembroke Pines or Orange County
Clear Path Behavioral Health provides Spravato (esketamine) treatment at outpatient psychiatric facilities in Pembroke Pines, Florida and Orange County, California. Patients access Spravato therapy by scheduling an initial psychiatric evaluation through the Clear Path website via Zocdoc integration. At that evaluation, a board-certified psychiatrist confirms TRD or MDSI diagnosis, reviews the required prior antidepressant trial history, and enrolls the patient in the FDA REMS program before any esketamine dose is administered.
Clear Path accepts most major insurance plans. Coverage for Spravato varies by plan and location; patients at the Pembroke Pines and Orange County locations are encouraged to use the insurance verification tool on the Clear Path website before the first appointment. Clear Path does not administer Spravato via telehealth. All sessions require in-person attendance at a REMS-certified facility.
Spravato (esketamine) is an S-enantiomer of ketamine formulated as a nasal spray and approved by the FDA in 2019 for treatment-resistant depression in adults. Unlike conventional antidepressants that target the monoamine system (serotonin, norepinephrine, dopamine), esketamine acts on N-methyl-D-aspartate (NMDA) glutamate receptors to rapidly restore synaptic connections in the prefrontal cortex. The American Psychiatric Association (APA) recognizes esketamine as a clinically significant advance for patients who have failed two or more adequate antidepressant trials.
At Clear Path Behavioral Health in Pembroke Pines and Orange County, Spravato is self-administered as a nasal spray during a supervised in-office session. Patients remain under observation for two hours following each dose to monitor blood pressure, sedation, and dissociative symptoms. Clear Path's board-certified psychiatrists and psychiatric physician assistants (PAs) conduct every evaluation and follow-up, ensuring patients receive direct face-to-face psychiatric care rather than a remote or delegated model.
What Is the Treatment Process for Spravato at Clear Path?
The Spravato treatment process at Clear Path follows FDA REMS requirements and a structured clinical protocol designed by board-certified psychiatrists. All sessions are in-person at our Pembroke Pines, FL or Orange County, CA locations. No remote or self-directed administration is permitted under the REMS program. The treatment process for Spravato sessions at Clear Path includes:
Psychiatric Evaluation and Eligibility Assessment
New patients complete a comprehensive 60-minute psychiatric evaluation conducted by a board-certified psychiatrist or psychiatric PA. The evaluation confirms TRD or MDSI diagnosis, documents the two or more failed antidepressant trials required for FDA eligibility, reviews current medications for contraindications, and establishes a baseline MADRS score. Patients with uncontrolled hypertension, active psychotic features, or a history of aneurysmal vascular disease are screened out at this stage.
Individualized Spravato Treatment Plan
Following the evaluation, the treating psychiatrist develops a personalized Spravato protocol that specifies the approved dosing schedule: 56 mg or 84 mg twice weekly for weeks 1 through 4, once weekly for weeks 5 through 8, and once weekly or once every two weeks during the maintenance phase. The plan integrates Spravato with a concurrently prescribed oral antidepressant, as required by the FDA label.
In-Office Spravato Administration and Observation
On each session day, the patient self-administers the esketamine nasal spray under direct clinical supervision at Clear Path's REMS-certified facility. Blood pressure is measured before dosing, 40 minutes post-dose, and at the 2-hour observation mark. Patients are monitored throughout the session for dissociation, dizziness, nausea, and sedation. Patients may not drive on the day of each session; a responsible adult must arrange transportation home.
Ongoing Psychiatric Monitoring and Adjustment
After each session, the treating clinician documents symptom change using the MADRS and Patient Health Questionnaire-9 (PHQ-9). Patients who do not show a clinically meaningful response (typically a 50% or greater reduction in MADRS score) by week 4 are reassessed for continued eligibility. Clear Path schedules in-person follow-up appointments monthly during the maintenance phase to adjust the oral antidepressant, address tolerability issues, and assess long-term treatment response.
Why Is Spravato an Important Advancement in Depression Treatment?
Spravato represents the first mechanistically novel antidepressant approved by the FDA since the introduction of SSRIs in the 1980s. Conventional antidepressants such as sertraline, escitalopram, and venlafaxine act on serotonin and norepinephrine reuptake transporters and require 4 to 8 weeks to produce a measurable antidepressant effect. For patients with treatment-resistant depression or acute suicidal ideation, that latency is clinically unacceptable. Esketamine produces statistically significant reductions in MADRS scores within 24 hours of the first dose, per the FDA-reviewed TRANSFORM-1 and TRANSFORM-2 clinical trials.
For patients in Pembroke Pines, FL and Orange County, CA who have exhausted multiple antidepressant regimens, Spravato offers a clinically validated pathway when pharmacological options appear limited. Clear Path's model ensures that every Spravato patient is evaluated by a board-certified psychiatrist, administered treatment in a REMS-certified facility, and monitored post-dose in accordance with FDA labeling. Unlike infusion-based ketamine clinics, which typically operate off-label, Spravato at Clear Path is covered under FDA approval and is eligible for insurance reimbursement from participating plans.
What Conditions Are Treated with Spravato Therapy?
Spravato (esketamine) nasal spray carries FDA approval for two specific psychiatric indications in adults: treatment-resistant depression (TRD), defined as inadequate response to at least two antidepressants of adequate dose and duration in the current depressive episode, and major depressive disorder with acute suicidal ideation or behavior (MDSI). Both indications require Spravato to be used in combination with an oral antidepressant. The conditions treated at Clear Path with Spravato therapy include:
Treatment-resistant depression is defined by the FDA as a failure to respond to at least two antidepressants of adequate dose and duration within the current depressive episode. Spravato targets NMDA glutamate receptors rather than the monoamine system, providing a mechanistically distinct option when SSRIs, SNRIs, or atypical antidepressants have produced insufficient symptom reduction as measured on validated scales such as the Montgomery-Asberg Depression Rating Scale (MADRS).
Major Depressive Disorder with Acute Suicidal Ideation (MDSI)
Major depressive disorder (MDD) with acute suicidal ideation or behavior (MDSI) is the second FDA-approved indication for Spravato, applicable when rapid reduction of suicidal ideation is clinically necessary. Clinical trials supporting this indication demonstrated significant reductions in MADRS score within 4 hours of the first dose, making Spravato a critical intervention when traditional antidepressants require 4 to 8 weeks to produce effect.
Anxiety Disorders Co-occurring with TRD
Generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder frequently co-occur with treatment-resistant depression. While Spravato's FDA approval is specific to TRD and MDSI, evidence from clinical studies suggests glutamatergic modulation reduces anxiety symptoms in patients with comorbid TRD. Clear Path's psychiatrists evaluate each patient's full diagnostic profile to determine whether Spravato is an appropriate component of a combined psychiatric treatment plan.
Post-Traumatic Stress Disorder (PTSD) with Co-occurring TRD
Post-traumatic stress disorder (PTSD) commonly co-occurs with major depressive disorder, and patients who meet criteria for both diagnoses and have failed two antidepressant trials are eligible for Spravato under the TRD indication. Per VA/DoD Clinical Practice Guidelines, adequate antidepressant treatment includes first-line agents such as sertraline and paroxetine before alternative pharmacological approaches are considered.
Bipolar Depression with TRD Criteria
Bipolar disorder presents with depressive episodes that often fail to remit on standard mood stabilizers such as lithium carbonate or valproate, or on antidepressant monotherapy. For patients with bipolar depression who meet TRD criteria, Clear Path's psychiatrists conduct a comprehensive psychiatric evaluation to assess Spravato candidacy, including a review of previous medication trials, current stabilizer regimen, and clinical risk factors for switching.
Testimonials
"Clearpath gave me the strength to overcome my anxiety. The compassionate therapists provided unwavering support, and I've found a renewed sense of purpose andtranquility in my life."
Veronica L.
Client from California
Testimonials
"Clearpath helped me regain control of my life. The personalized treatment plan and the caring staff made all the difference. I am now on a path to recovery and happiness."
Michael S.
Client from Florida
Choose Clear Path
How to Choose a Spravato Treatment Program
Selecting the right Spravato (esketamine) treatment program requires verifying that the provider operates a REMS-certified facility, employs board-certified psychiatrists, and follows the FDA-required induction and maintenance dosing schedule. The following steps help prospective patients evaluate Spravato programs in Pembroke Pines, Orange County, and elsewhere.
Confirm You Meet FDA Eligibility Criteria
Spravato requires documented failure of at least two oral antidepressants of adequate dose and duration in the current depressive episode (TRD), or a current diagnosis of MDD with acute suicidal ideation or behavior (MDSI). Gather records from previous prescribers that document the antidepressants tried, dosages, and durations before contacting a Spravato clinic.
Verify the Facility Is REMS-Certified
The FDA Spravato REMS program requires every facility that dispenses or administers esketamine to be individually certified. Confirm that the clinic appears in the REMS registry maintained by Janssen Pharmaceuticals and that sessions are conducted and supervised by a licensed healthcare provider on-site, not delegated to non-clinical staff.
Confirm Board-Certified Psychiatric Supervision
Spravato is a Schedule III controlled substance with dissociative and blood pressure side effects that require clinical management. The treating provider should be a board-certified psychiatrist or a psychiatric physician assistant supervised by a board-certified psychiatrist, not a primary care provider or registered nurse acting without psychiatric oversight.
Review the Dosing Protocol
The FDA-approved induction schedule is 56 mg or 84 mg twice weekly for four weeks. Maintenance dosing is once weekly for weeks 5 through 8, then once weekly or once every two weeks from week 9 onward, based on clinical response. Programs that deviate from this schedule without documented clinical rationale are not following FDA labeling.
Confirm Concurrent Oral Antidepressant Management
The FDA label requires Spravato to be used in combination with an oral antidepressant. Programs that administer esketamine without prescribing and monitoring a concurrent oral antidepressant are operating outside FDA-approved use. Ask specifically which oral antidepressant will be prescribed and who manages titration and follow-up.
Verify Transportation and Observation Policies
REMS requirements mandate that patients remain at the certified healthcare setting for at least two hours after each dose and not drive or operate hazardous machinery on session days. Programs that discharge patients within two hours or permit driving are in REMS non-compliance. Confirm the clinic's post-dose observation and transportation policies before booking.
Confirm Insurance Coverage and Out-of-Pocket Costs
Unlike off-label IV ketamine infusions, FDA-approved Spravato is eligible for insurance reimbursement from most major plans. Request a pre-authorization letter from your insurer before the first session. Clear Path's Pembroke Pines and Orange County locations accept most major insurance plans; use the insurance verification tool on the Clear Path website to check in-network status before your evaluation appointment.
What Are the Clinical Benefits of Spravato at Clear Path?
Spravato delivers rapid antidepressant effects by targeting NMDA glutamate receptors in the prefrontal cortex, restoring synaptic density that major depressive disorder reduces over time. In the TRANSFORM-2 Phase III trial reviewed by the FDA, esketamine plus a newly initiated oral antidepressant produced significantly greater reductions in MADRS score at day 28 compared to placebo nasal spray plus oral antidepressant. The SUSTAIN-1 trial demonstrated that patients who responded to Spravato during the induction phase and continued maintenance dosing experienced significantly longer time to relapse than patients who discontinued esketamine. For adults with TRD in Pembroke Pines and Orange County, Spravato provides a time-to-response advantage that conventional antidepressants cannot match.
Clear Path's in-person Spravato program delivers the clinical oversight that the FDA REMS program mandates. Patients benefit from direct psychiatric supervision at every session, eliminating the safety gaps that occur in remote or self-administered ketamine programs. The Clear Path model integrates Spravato sessions with ongoing medication management, meaning that oral antidepressant dosing, tolerability, and therapeutic response are evaluated at every monthly follow-up appointment. This coordinated approach aligns with APA treatment guidelines for treatment-resistant depression, which recommend combining pharmacological interventions with structured clinical monitoring.
Who Is a Candidate for Spravato (Esketamine) Treatment?
Spravato is an FDA-approved treatment specifically for adults aged 18 and older who meet one of two diagnostic criteria: treatment-resistant depression (TRD) confirmed by at least two failed antidepressant trials of adequate dose and duration in the current episode, or major depressive disorder with acute suicidal ideation or behavior (MDSI) requiring rapid pharmacological intervention. Clear Path's psychiatrists in Pembroke Pines and Orange County conduct the full eligibility assessment before initiating treatment.
Adults who qualify for Spravato at Clear Path include:
Adults with treatment-resistant depression (TRD) who have not responded to at least two antidepressant medications at adequate dose and duration in the current depressive episode
Adults with major depressive disorder (MDD) with acute suicidal ideation or behavior (MDSI) who require rapid pharmacological intervention
Adults with co-occurring generalized anxiety disorder (GAD), PTSD, or bipolar depression who also meet TRD criteria
Adults with a current oral antidepressant prescription, as Spravato is FDA-required to be used in combination with an oral antidepressant
Spravato is not indicated for patients under 18, patients with active psychosis or uncontrolled hypertension, or patients seeking Spravato as a first-line treatment. Clear Path does not administer esketamine outside of its board-certified psychiatric facilities in Pembroke Pines, FL and Orange County, CA.
Frequently Asked Questions About Spravato Treatment
Clinical answers to common questions about esketamine therapy at Clear Path
Is Spravato the same as ketamine infusions?
Spravato (esketamine) and IV ketamine both act on NMDA glutamate receptors, but they are not the same treatment. Spravato is the S-enantiomer of ketamine, is FDA-approved specifically for TRD and MDSI, is self-administered as a nasal spray rather than infused intravenously, and is subject to the REMS program. IV ketamine infusions are administered off-label, are not FDA-approved for depression, and are not covered by most insurance plans. At Clear Path, only FDA-approved Spravato is offered.
Is Spravato covered by insurance?
Spravato is an FDA-approved treatment and is eligible for coverage under most major insurance plans, in contrast to off-label IV ketamine infusions which are rarely reimbursed. Coverage terms vary by plan, insurer, and location. Clear Path's Pembroke Pines and Orange County locations accept most major insurance plans. Patients are advised to request a pre-authorization determination from their insurer before scheduling the first session, and to use the insurance verification tool on the Clear Path website.
How long does a Spravato session take?
Each Spravato session at Clear Path requires approximately 2 to 2.5 hours of time at the facility. Self-administration of the nasal spray takes approximately 10 minutes, followed by a mandatory two-hour post-dose observation period required by the FDA REMS program. During the observation period, blood pressure is measured at 40 minutes and at two hours, and the clinical team monitors for dissociation, dizziness, and sedation. Patients may not drive on the day of any Spravato session.
How many Spravato sessions are required?
The FDA-approved induction schedule requires twice-weekly sessions for four weeks (8 total sessions). During the maintenance phase, sessions reduce to once weekly for weeks 5 through 8, then once weekly or every two weeks from week 9 onward depending on clinical response. Clear Path's psychiatrists re-evaluate treatment continuation at week 4 using MADRS scores. Patients who do not show a clinically meaningful response by week 4 are reviewed for alternative treatment options.
What are the side effects of Spravato?
The most common adverse effects of Spravato reported in FDA clinical trials are dissociation (occurring in approximately 25 to 40% of sessions), dizziness, nausea, sedation, and transient blood pressure elevation. These effects are most intense in the first hour after dosing and typically resolve before the two-hour observation period ends. Serious adverse events, including sustained hypertension or loss of consciousness, are rare and are managed at Clear Path's facility by the clinical team present during every session.
Clear Path's board-certified psychiatrists in Pembroke Pines, FL and Orange County, CA conduct comprehensive psychiatric evaluations to determine Spravato eligibility and develop a personalized esketamine treatment plan aligned with FDA labeling and REMS requirements.
